Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Surmodics Inc (SRDX)

Surmodics Inc (SRDX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 650,638
  • Shares Outstanding, K 13,606
  • Annual Sales, $ 100,080 K
  • Annual Income, $ 7,590 K
  • 60-Month Beta 1.00
  • Price/Sales 6.43
  • Price/Cash Flow 36.37
  • Price/Book 5.15

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate 0.10
  • Number of Estimates 1
  • High Estimate 0.10
  • Low Estimate 0.10
  • Prior Year 0.15
  • Growth Rate Est. (year over year) -33.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
40.55 +16.05%
on 07/09/20
48.94 -3.84%
on 07/30/20
+4.06 (+9.44%)
since 07/02/20
3-Month
33.45 +40.69%
on 05/14/20
48.94 -3.84%
on 07/30/20
+10.87 (+30.04%)
since 05/04/20
52-Week
22.06 +113.33%
on 03/18/20
48.94 -3.84%
on 07/30/20
+1.48 (+3.25%)
since 08/02/19

Most Recent Stories

More News
Surmodics to Webcast Third Quarter Fiscal 2020 Earnings Conference Call on August 5

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it will host a live webcast of its third quarter...

SRDX : 47.06 (-1.59%)
Here's Why You Should Add AMN Healthcare to Your Portfolio

Investor confidence is high in AMN Healthcare (AMN) stock, thanks to solid prospects.

DGX : 128.10 (-1.47%)
SRDX : 47.06 (-1.59%)
LH : 194.77 (-0.64%)
AMN : 55.11 (+0.57%)
PerkinElmer (PKI) Launches DBS Test for Coronavirus Diagnosis

PerkinElmer (PKI) unveils DBS-based test, being marketed as a CE-IVD test, while intending to apply for its FDA EUA soon.

DGX : 128.10 (-1.47%)
PKI : 120.82 (-0.78%)
SRDX : 47.06 (-1.59%)
LH : 194.77 (-0.64%)
Surmodics Inc Has Returned 49.3% Since SmarTrend Recommendation (SRDX)

SmarTrend identified an Uptrend for Surmodics Inc (NASDAQ:SRDX) on March 25th, 2020 at $30.35. In approximately 4 months, Surmodics Inc has returned 49.29% as of today's recent price of $45.31.

SRDX : 47.06 (-1.59%)
Masimo (MASI) Introduces Automation and Connectivity Solution

Masimo's (MASI) UniView: 60 leverages the Masimo Hospital Automation platform to boost clinical workflows.

DGX : 128.10 (-1.47%)
MASI : 217.19 (-0.49%)
SRDX : 47.06 (-1.59%)
LH : 194.77 (-0.64%)
Here's Why You Should Retain Merit Medical (MMSI) for Now

Investor confidence is high on Merit Medical (MMSI) stock, thanks to solid prospects.

DGX : 128.10 (-1.47%)
SRDX : 47.06 (-1.59%)
MMSI : 42.93 (-1.99%)
LH : 194.77 (-0.64%)
Shares of SRDX Up 42.4% Since Uptrend Call on Shares

SmarTrend identified an Uptrend for Surmodics Inc (NASDAQ:SRDX) on March 25th, 2020 at $30.35. In approximately 4 months, Surmodics Inc has returned 42.41% as of today's recent price of $43.22.

SRDX : 47.06 (-1.59%)
VREX vs. SRDX: Which Stock Is the Better Value Option?

VREX vs. SRDX: Which Stock Is the Better Value Option?

VREX : 16.27 (+1.81%)
SRDX : 47.06 (-1.59%)
QIAGEN (QGEN) Reports Encouraging Preliminary Q2 Results

Preliminary net revenues for second-quarter 2020 improved 18-19% at CER.

DGX : 128.10 (-1.47%)
SRDX : 47.06 (-1.59%)
QGEN : 47.49 (-2.94%)
LH : 194.77 (-0.64%)
Here's Why You Should Hold on to Nevro (NVRO) Stock Now

Investor confidence is high on Nevro (NVRO), thanks to solid prospects

DGX : 128.10 (-1.47%)
SRDX : 47.06 (-1.59%)
LH : 194.77 (-0.64%)
NVRO : 132.12 (-2.93%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

See More Share

Trade SRDX with:

Business Summary

SurModics, Inc. is a leading provider of surface modification technologies in the areas of biocompatibility, site specific drug delivery, biological cell encapsulation, and medical diagnostics. SurModics partners with the world's foremost medical device, pharmaceutical and life science companies to bring...

See More

Key Turning Points

2nd Resistance Point 48.71
1st Resistance Point 47.89
Last Price 47.06
1st Support Level 46.10
2nd Support Level 45.13

See More

52-Week High 48.94
Last Price 47.06
Fibonacci 61.8% 38.67
Fibonacci 50% 35.50
Fibonacci 38.2% 32.33
52-Week Low 22.06

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar